Research Grade Vilobelimab (DHB90008)

Catalog No.

DHB90008

Expression system

Mammalian Cells

Species reactivity

Human

Host species

Chimeric

Isotype

IgG4-kappa

Clonality

Monoclonal

Target

CPAMD4, C5, C3 and PZP-like alpha-2-macroglobulin domain-containing protein 4, Complement C5

Concentration

3.13 mg/ml

Endotoxin level

Please contact with the lab for this information.

Purity

>95% as determined by SDS-PAGE.

Purification

Protein A/G purified from cell culture supernatant.

Accession

P01031

Applications

Research Grade Biosimilar

Form

Liquid

Storage buffer

0.01M PBS, pH 7.4.

Stability and Storage

Use a manual defrost freezer and avoid repeated freeze-thaw cycles. Store at 4°C short term (1-2 weeks). Store at -20°C 12 months. Store at -80°C long term.

Alternative Names

CaCP-29, IFX-1, CAS: 2250440-41-4

Clone ID

Vilobelimab

Anti-C5a antibody IFX-1 (vilobelimab) treatment versus best supportive care for patients with severe COVID-19 (PANAMO): an exploratory, open-label, phase 2 randomised controlled trial, PMID: 33015643

Complement inhibition in ANCA vasculitis, PMID: 31631015

New Therapeutic Targets in Antineutrophil Cytoplasm Antibody-Associated Vasculitis, PMID: 32562366

Pyoderma gangrenosum: proposed pathogenesis and current use of biologics with an emphasis on complement C5a inhibitor IFX-1, PMID: 32880206

Clinical efficacy of complement C5a inhibition by IFX-1 in hidradenitis suppurativa: an open-label single-arm trial in patients not eligible for adalimumab, PMID: 31954061

Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider, PMID: 33589438

Document Download

Research Grade Vilobelimab.pdf